
Work Here?
Zentiva makes branded generic medicines in Europe. Its products are off-patent drugs sold under Zentiva brands with the same active ingredients and safety as the originals, usually at lower cost. The company distinguishes itself through a long history and growth by acquisitions to expand across Europe, especially after becoming independent under private equity. Its goal is to be a leading European branded generics platform by widening its product lineup and geographic reach.
Industries
Healthcare
Company Size
1,001-5,000
Company Stage
Acquired
Total Funding
N/A
Headquarters
Prague, Czechia
Founded
2003
See people who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?
Total Funding
$0
Below
Industry Average
Funded Over
2 Rounds
Health Insurance
Life Insurance
Paid Vacation
Paid Sick Leave
Meal Benefits
Relocation Assistance
Flexible Work Hours
Performance Bonus
Training Programs
Professional Development Budget
Company Social Events
Demonstrating accountability: Zentiva receives prestigious ESG Transparency Award 2025. PRAGUE, Nov. 28, 2025 /PRNewswire/ - Zentiva, a leading European generics pharmaceutical company, has received the esteemed ESG Transparency Award 2025 by the EUPD Group. This award recognises companies that excel in clarity, structure and transparency in their Environmental, Social and Governance (ESG) reporting. The awards were presented at the ESG Summit 2025, as part of the European Sustainability Week 2025, hosted by the EUPD Group. The recognition is a testament to the efforts of industry leaders who have embedded sustainability in their business strategy and communicate it transparently according to relevant standards. Zentiva received recognition at the Excellence Level of the ESG Transparency Award 2025 for its high degree of clarity, accessibility and transparency in sustainability reporting. The Excellence Level distinction places Zentiva among the top organisations in Europe in terms of transparent reporting of its ESG disclosures. The company excelled in the presentation of a well-structured and strategically grounded sustainability approach that incorporates current European requirements into governance and reporting processes. Furthermore, the disclosure of climate related information, including the use of renewable electricity at European production sites and its integration into a broader long term climate strategy reached a high level of transparency. In addition, Zentiva offered a full calculation of the indirect carbon footprint with externally reviewed methodology to strengthen data integrity and clearly explained its governance structures, highlighting the role of the Audit Committee in approving sustainability related plans. These results underline the determination of Zentiva to strive to drive positive change for society and the environment. Steffen Klink, COO of the EUPD Group commented: "We proudly congratulate Zentiva on its exceptional commitment to transparent ESG communication, clearly demonstrating accountability by publicly detailing material impacts, risks, and opportunities across key environmental, social, and governance areas. This dedication to holistic performance, including ambitious decarbonization targets and robust global policies on ethical conduct and responsible sourcing, sets a definitive benchmark for industry excellence." Ines Windisch, Head of Corporate Affairs & Sustainability at Zentiva, commented: "We are truly proud to receive this award for our sustainability reporting. It acknowledges a journey that is far more than just compliance - it is about learning, testing, piloting, and acting with courage and transparency. At Zentiva we understand small steps can create a big impact, and we must act today for a sustainable tomorrow. Sustainability is not just a responsibility; it is an opportunity for people and partners to create a lasting positive impact for future generations. This award is a milestone that inspires us to keep moving forward." About Zentiva Zentiva provides health and wellbeing for all generations, with focus on developing, producing, and delivering high-quality, affordable medicines to more than 100 million people in over 30 countries across Europe and beyond. Zentiva has four wholly-owned manufacturing sites and a broad network of external manufacturing partners to ensure supply security. Zentiva employs more than 5,000 unique talents, bonded together by a commitment to the people who depend on its medicines every day. Visit Healthcare at www.zentiva.com About the ESG Transparency Award The ESG TRANSPARENCY AWARD honours European organisations that have already anchored forward-looking sustainability concepts in their company and communicate these transparently in the form of a sustainability report. These pioneers serve as role models because they change the world and prove that profitability and sustainability are not opposites, but successful strategies for a future worth living. The EUPD Group has developed the ESG Transparency Evaluation Standard to objectively assess transparency, accountability and structural quality of ESG reporting. It draws on the most relevant European and international guidelines of sustainability reporting and serves as the methodical basis of the ESG Transparency Award. www.esg-transparency-award.de/en/ SOURCE Zentiva
India's Economic Times reported last month that Aurobindo Pharma, one of India's largest generics manufacturers, had been leading the race to acquire Zentiva with an offer reportedly valued at up to $5.5 billion.
American investment firm GTCR is acquiring Czech drug manufacturer Zentiva from Advent International for €4.1 billion, including debts, as reported by the Financial Times. This sale marks a significant increase from the €1.9 billion Advent paid in 2018. The transaction, resulting from a bidding process, highlights growing investor interest in stable pharmaceutical companies in the region. The deal is expected to be officially announced soon.
Aurobindo Pharma is set to acquire Prague-based Zentiva for $5-5.5 billion, marking the largest-ever acquisition by an Indian pharma company. Competing with US firm GTCR, Aurobindo has secured a $4.75 billion credit line from MUFG, with the remaining $800 million from internal funds. This acquisition will enhance Aurobindo's European presence, especially in Eastern Europe. Zentiva's 2024 revenues are projected at €1.7 billion with an EBITDA of €400 million.
Ensuring Fair Access to Medicines for AllPRAGUE and BRUSSELS, May 22, 2025 /PRNewswire/ -- Zentiva supported Euractiv's Health Policy Conference in Brussels, where its CEO, Steffen Saltofte, joined senior EU policymakers in the opening panel titled "The EU Pharmaceutical Legislation – Ensuring Fair Access to Medicines for All."Copyright: Euractiv, 2025 - From left to right: Rainer Becker, Director for Medical Products and Innovation at DG SANTE in the European Commission; Stine Bosse, Member of the European Parliament and Vice-Chair of the SANT Committee; Ondřej Knotek, Member of the European Parliament and of the SANT Committee; Steffen Saltofte, CEO Zentiva; Anna Gumbau, moderator Euractiv (PRNewsfoto/Zentiva)Representing Europe's off-patent medicine sector, Steffen Saltofte called for a unified approach to reshape pharmaceutical policy with patients at the centre. He emphasised the need to bring together all healthcare stakeholders — from innovators to the off-patent industry, from regulators to policymakers — to fulfil the promise of health as a fundamental right for all."We need sustainable healthcare that is resilient and that people can trust," said Steffen Saltofte. "Our EU-based plants delivered throughout COVID and recent shortages — but continued resilience is only possible with a systemic framework that ensures fair and simple rules, predictable pricing, and an aligned policy approach that truly puts patients first. If we want equal access to medicines, we must invest in the system. That means working together to secure medicines for all — across availability, affordability, and accessibility. This demands fair, forward-looking rules and a shared commitment to Europe's healthcare sovereignty
Find jobs on Simplify and start your career today
Industries
Healthcare
Company Size
1,001-5,000
Company Stage
Acquired
Total Funding
N/A
Headquarters
Prague, Czechia
Founded
2003
Find jobs on Simplify and start your career today